Enorama Pharma AB (OSTO:ERMA) Asset Turnover: -0.01 (As of Mar. 2026)


OSTO:ERMA Enorama Pharma AB OSTO:ERMA
29 GF Score
Price kr0.30
GF Value kr0.41
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Asset Turnover?

Enorama Pharma AB OSTO:ERMA 29 Asset Turnover is -0.01 as of Mar. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 29/100 and a GF Value™ of kr0.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Enorama Pharma AB's Revenue for the three months ended in Mar. 2026 was kr-0.11 Mil. Enorama Pharma AB's Total Assets for the quarter that ended in Mar. 2026 was kr15.61 Mil. Therefore, Enorama Pharma AB's Asset Turnover for the quarter that ended in Mar. 2026 was -0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. Enorama Pharma AB's annualized ROE % for the quarter that ended in Mar. 2026 was 168.36%. It is also linked to ROA % through Du Pont Formula. Enorama Pharma AB's annualized ROA % for the quarter that ended in Mar. 2026 was -324.12%.


Enorama Pharma AB  (OSTO:ERMA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Enorama Pharma AB's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-50.58/-30.043
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-50.58 / -0.436)*(-0.436 / 15.6055)*(15.6055/ -30.043)
=Net Margin %*Asset Turnover*Equity Multiplier
=11600.92 %*-0.0279*-0.5194
=ROA %*Equity Multiplier
=-324.12 %*-0.5194
=168.36 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Enorama Pharma AB's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-50.58/15.6055
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-50.58 / -0.436)*(-0.436 / 15.6055)
=Net Margin %*Asset Turnover
=11600.92 %*-0.0279
=-324.12 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Enorama Pharma AB Asset Turnover Related Terms


Enorama Pharma AB Asset Turnover Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB Asset Turnover Chart

Enorama Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.14 0.03 0.63 0.23

Enorama Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 -0.01 0.17 -0.01

OSTO:ERMA vs ZTS, UTHR, VTRS: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enorama Pharma AB Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Enorama Pharma AB's Asset Turnover falls into.


OSTO:ERMA
29GF Score
Enorama Pharma AB OSTO:ERMA
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Enorama Pharma AB's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=2.739/( (15.894+8.262)/ 2 )
=2.739/12.078
=0.23

Enorama Pharma AB's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-0.109/( (8.262+22.949)/ 2 )
=-0.109/15.6055
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of -0.01 mean?
Enorama Pharma AB (OSTO:ERMA) has a Asset Turnover of -0.01 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Enorama Pharma AB and its competitors.
Is Enorama Pharma AB's Asset Turnover too high?
Enorama Pharma AB's current Asset Turnover is -0.01. Overall, Enorama Pharma AB has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Asset Turnover compare to ZTS and UTHR?
Enorama Pharma AB's Asset Turnover of -0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Enorama Pharma AB and its competitors. Enorama Pharma AB's current Asset Turnover is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.41, compared to a current price of kr0.30 — trading 27.8% below its estimated fair value. The current Asset Turnover is -0.01. Enorama Pharma AB's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Asset Turnover is -0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.30 is trading 27.8% below its estimated GF Value™ of kr0.41. GuruFocus considers Enorama Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:ERMA:

  • Asset Turnover: -0.01
  • GF Value™: kr0.41 vs. price of kr0.30 (27.8% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
29GF Score

Get the complete analysis for OSTO:ERMA

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.30
Price
kr0.41
GF Value